“…The reversible or noncovalent inhibitors such as 1,2,3‐trimethyl‐8‐(pentafluorophenylmethoxy) imidazole [1,2‐α] pyridinium iodide (TMPFPIP), a derivative of the imidazole [1,2‐α]pyridine belonging to SCH28080 series, are K + ‐competitive inhibitors and bind with high affinity to the E2 conformation of the H + K + ‐ATPase, which has a low‐affinity binding site for K + . The modeled E2 conformation proposed a single concerted ligand binding site for TMPFPIP occupying the vestibule created by TM5‐6 loop (L809, P810, L811, and C813), TM6 (I814, I816, and F818), and TM8 (Y925, T929, and F932) (18,54). SCH28080 binds to the region of luminal surface consisting of TM4 (A335), TM5‐6 loop (L809), TM6 (C813), and TM8 (Y922 and I940) (55).…”